CA2295389A1 - Method of treatment of nausea, vomiting, and other disorders using estrogens - Google Patents

Method of treatment of nausea, vomiting, and other disorders using estrogens Download PDF

Info

Publication number
CA2295389A1
CA2295389A1 CA002295389A CA2295389A CA2295389A1 CA 2295389 A1 CA2295389 A1 CA 2295389A1 CA 002295389 A CA002295389 A CA 002295389A CA 2295389 A CA2295389 A CA 2295389A CA 2295389 A1 CA2295389 A1 CA 2295389A1
Authority
CA
Canada
Prior art keywords
disorders
treatment
estrogens
nausea
vomiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002295389A
Other languages
French (fr)
Other versions
CA2295389C (en
Inventor
Joy Ann Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002295389A priority Critical patent/CA2295389C/en
Publication of CA2295389A1 publication Critical patent/CA2295389A1/en
Application granted granted Critical
Publication of CA2295389C publication Critical patent/CA2295389C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The use of estrone or derivatives of estrone, equilin, or equilenin, includi ng pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds as a therapeutic agent in humans or in animals is claimed. The asserted use is as an antiemetic agent or for the treatment of other disorders that can be ameliorated by noncompetiti ve antagonism of the 5-hydroxytryptamine type 3 receptor.
CA002295389A 2000-01-04 2000-01-04 Method of treatment of nausea, vomiting, and other disorders using estrogens Expired - Lifetime CA2295389C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002295389A CA2295389C (en) 2000-01-04 2000-01-04 Method of treatment of nausea, vomiting, and other disorders using estrogens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002295389A CA2295389C (en) 2000-01-04 2000-01-04 Method of treatment of nausea, vomiting, and other disorders using estrogens

Publications (2)

Publication Number Publication Date
CA2295389A1 true CA2295389A1 (en) 2001-07-04
CA2295389C CA2295389C (en) 2006-07-11

Family

ID=4165054

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295389A Expired - Lifetime CA2295389C (en) 2000-01-04 2000-01-04 Method of treatment of nausea, vomiting, and other disorders using estrogens

Country Status (1)

Country Link
CA (1) CA2295389C (en)

Also Published As

Publication number Publication date
CA2295389C (en) 2006-07-11

Similar Documents

Publication Publication Date Title
NZ514574A (en) Novel method of treatment
IL101162A0 (en) Pharmaceutical compositions for oral administration comprising an indole derivative
WO2004066910A3 (en) Controlled release modifying complex and pharmaceutical compositions thereof
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
HK1054918A1 (en) Compounds and compositions for delivering active agents
PL366430A1 (en) Sustained release formulations of oxymorphone
MXPA01008611A (en) Compounds and compositions for delivering active agents.
MXPA04003807A (en) Pharmaceutical compositions of 5, 7, 14-triazatetracyclo [10.3.1.0(2,11).0(4,9)] -hexadeca -2(11) 3, 5, 7, 9-pentaene.
HK1084015A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
EP1232757A4 (en) Remedies for diseases in association with decrease in bone mass
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2004000840A3 (en) Quinuclidine derivatives and pharmaceutical compositions containing the same
NO954878L (en) pyrrole
SE9903997D0 (en) New compounds
MXPA05012955A (en) Pharmaceutical compositions of atorvastatin.
AU2003290015A1 (en) Mastitis treatment
WO2000054780A3 (en) Corticosteroid formulation
AP2001002084A0 (en) Orally administered controlled delivery system for once daily adminstration of ciprofloxacin
CA2295389A1 (en) Method of treatment of nausea, vomiting, and other disorders using estrogens
MY133682A (en) Substituted pyrroles
ES2179729A1 (en) Solid, water-dispersible, oral pharmaceutical form comprising rifampicin, isoniazid and pyridoxine hydrochloride, method for obtaining and presenting said pharmaceutical form
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
ES2184561A1 (en) Solid, orally administered, water-dispersible pharmaceutical form for the treatment of tuberculosis, containing rifampicin, isoniazid, pirazinamide and pyridoxine hydrochloride, method for obtaining and presentation form of said pharmaceutical form
BG106078A (en) Thio-oxindole derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200106